Legend Biotech Corporation - American Depositary Shares (LEGN)
Frequently Asked Questions About Legend Biotech Corporation - American Depositary Shares (LEGN)
Does Legend Biotech have any partnerships?
Yes, Legend Biotech has established partnerships with various organizations, including Johnson & Johnson’s Janssen Pharmaceuticals. These collaborations focus on sharing expertise, resources, and funding to accelerate the development of new therapies.
How does Legend Biotech contribute to the community?
Legend Biotech contributes to the community through various initiatives, including outreach programs, partnerships with cancer support organizations, and efforts to raise awareness about cancer treatments and patient care.
How does Legend Biotech ensure the quality of its products?
Legend Biotech ensures product quality through stringent manufacturing processes, adherence to Good Manufacturing Practices (GMP), and comprehensive quality control measures that encompass all stages of production.
How is Legend Biotech funded?
Legend Biotech is funded through a combination of public equity offerings, private investments, and strategic partnerships. These funding sources enable the company to support its research and development initiatives.
Is Legend Biotech publicly traded?
Yes, Legend Biotech Corporation is publicly traded on the Nasdaq stock exchange under the ticker symbol LEGN. It went public in 2020, allowing it to raise capital for further research and development.
What are the key areas of research for Legend Biotech?
Legend Biotech focuses primarily on the research and development of cell therapies for hematological cancers, including multiple myeloma and other blood-related malignancies. They are also exploring therapies for solid tumors.
What challenges does Legend Biotech face?
Like many biotech companies, Legend Biotech faces challenges such as regulatory hurdles, competition in the rapidly evolving field of cell therapy, and the need for continuous funding to support research and clinical development.
What does Legend Biotech Corporation do?
Legend Biotech Corporation is a biotechnology company focused on developing and commercializing innovative cell therapies for patients with hematological malignancies and solid tumors. The company is particularly known for its work in CAR-T (chimeric antigen receptor T-cell) therapy, which harnesses the patient's own immune system to fight cancer.
What future developments can be expected from Legend Biotech?
Future developments at Legend Biotech may include the expansion of its product pipeline, advancements in CAR-T therapy applications, ongoing clinical trials for new treatments, and potential collaborations for joint research initiatives.
What is Legend Biotech's approach to clinical trials?
Legend Biotech employs a rigorous approach to clinical trials, prioritizing patient safety and scientific integrity. They conduct Phase 1, 2, and 3 trials, often in partnership with leading research institutions and hospitals to evaluate the efficacy and safety of their therapies.
What is the company’s mission statement?
Legend Biotech's mission is to innovate and deliver transformative cell therapies that improve the lives of patients battling cancer. The company is dedicated to pioneering advancements in biotechnology to provide hope to those in need.
What is the primary product of Legend Biotech?
Legend Biotech's primary product is LCAR-B38M, also known as Carvykti. This cellular therapy is designed for the treatment of multiple myeloma and has shown promising results in clinical trials.
What is the significance of the company’s stock symbol, LEGN?
The stock symbol LEGN represents Legend Biotech Corporation on the Nasdaq stock exchange. Investors can use this symbol to track the company’s stock performance, trade shares, and access financial information.
What market is Legend Biotech targeting?
Legend Biotech primarily targets the oncology market, particularly focusing on therapies for hematological malignancies, including multiple myeloma, and potentially expanding into solid tumors in the future.
What regulatory approvals has Legend Biotech received?
Legend Biotech has received regulatory approval for its lead product, Carvykti, from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma, making it a significant milestone in the company’s journey.
When was Legend Biotech Corporation founded?
Legend Biotech Corporation was founded in 2014. It has rapidly grown in the biotech sector, aiming to address unmet medical needs in oncology through the development of cutting-edge therapies.
Where is Legend Biotech Corporation headquartered?
Legend Biotech Corporation is headquartered in Somerset, New Jersey, United States. This location serves as a strategic hub for its research, development, and corporate operations.
Who are the key executives at Legend Biotech?
Key executives at Legend Biotech include its CEO, Dr.ramin khan, and other top leaders with extensive experience in biotechnology and pharmaceutical industries. The management team is committed to advancing the company’s mission and expanding its portfolio.
Who is the target patient demographic for Legend Biotech’s therapies?
The target patient demographic for Legend Biotech’s therapies primarily includes individuals diagnosed with multiple myeloma and other hematological cancers. The therapies are designed to treat patients who may have exhausted other treatment options.
What is the current price of Legend Biotech Corporation - American Depositary Shares?
The current price of Legend Biotech Corporation - American Depositary Shares is 31.34
When was Legend Biotech Corporation - American Depositary Shares last traded?
The last trade of Legend Biotech Corporation - American Depositary Shares was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Legend Biotech Corporation - American Depositary Shares?
The market capitalization of Legend Biotech Corporation - American Depositary Shares is 9.67B
How many shares of Legend Biotech Corporation - American Depositary Shares are outstanding?
Legend Biotech Corporation - American Depositary Shares has 308.46M shares outstanding.